Literature DB >> 2059756

Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis.

H J Deeg1, T R Spitzer, M Cottler-Fox, R Cahill, L W Pickle.   

Abstract

Intensive chemoradiotherapy conditioning regimens and acute graft-versus-host disease (GVHD) are both associated with significant morbidity and mortality after bone marrow transplantation. In this study, we investigated whether the conditioning regimen affected the development of acute GVHD. Thirty-four patients, four with severe aplastic anemia and 30 with a lymphohemopoietic malignancy, were prepared for transplantation either with cyclophosphamide (CY) alone, with CY combined with total body irradiation (TBI) or CY combined with etoposide and either TBI or busulfan. GVHD prophylaxis included methotrexate (MTX 10 mg/m2) given on days 1, 3 and 6, and daily cyclosporine (CSP) on days--1 through 180. The overall incidence of acute GVHD was 36% (15% for HLA identical, 87% for HLA non-identical recipients). However, when assessed by the severity of conditioning regimen-related toxicity, the incidence of GVHD grades II-IV (HLA identical; HLA non-identical) was 0% (0%; 0%), 37% (20%; 67%) and 50% (22%; 100%) for patients with mild, moderate and severe toxicity, respectively. Compliance with GVHD prophylaxis declined with increasing intensity and toxicity of the conditioning regimen. These data suggest that a regimen of three doses of MTX and daily CSP is as effective as four doses of MTX/CSP for GVHD prophylaxis in patients given HLA identical marrow grafts. However, GVHD regimen compliance and efficacy of GVHD prevention are inversely related to the intensity of the conditioning regimen.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2059756

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  14 in total

Review 1.  Who is fit for allogeneic transplantation?

Authors:  H Joachim Deeg; Brenda M Sandmaier
Journal:  Blood       Date:  2010-08-11       Impact factor: 22.113

2.  Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy.

Authors:  Yasuyuki Arai; June Takeda; Kazunari Aoki; Tadakazu Kondo; Satoshi Takahashi; Yasushi Onishi; Yukiyasu Ozawa; Nobuyuki Aotsuka; Yasuji Kouzai; Hirohisa Nakamae; Shuichi Ota; Chiaki Nakaseko; Hiroki Yamaguchi; Koji Kato; Yoshiko Atsuta; Akiyoshi Takami
Journal:  Blood       Date:  2015-06-01       Impact factor: 22.113

3.  Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy.

Authors:  H Joachim Deeg; Margaret O'Donnell; Jakub Tolar; Rajni Agarwal; Richard E Harris; Stephen A Feig; Mary C Territo; Robert H Collins; Peter A McSweeney; Edward A Copelan; Shakila P Khan; Ann Woolfrey; Barry Storer
Journal:  Blood       Date:  2006-05-09       Impact factor: 22.113

4.  Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.

Authors:  G R Hill; T Teshima; A Gerbitz; L Pan; K R Cooke; Y S Brinson; J M Crawford; J L Ferrara
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

Review 5.  Idiopathic pneumonia syndrome after bone marrow transplantation: the role of pre-transplant radiation conditioning and local cytokine dysregulation in promoting lung inflammation and fibrosis.

Authors:  G Shankar; D A Cohen
Journal:  Int J Exp Pathol       Date:  2001-04       Impact factor: 1.925

6.  Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS.

Authors:  Aaron T Gerds; Ted A Gooley; Elihu H Estey; Frederick R Appelbaum; H Joachim Deeg; Bart L Scott
Journal:  Biol Blood Marrow Transplant       Date:  2012-01-16       Impact factor: 5.742

7.  Comparison of 2 preparative regimens for stem cell transplantation from HLA-matched sibling donors in patients with advanced myelodysplastic syndrome.

Authors:  Yoo-Jin Kim; Dong-Wook Kim; Seok Lee; Chang-Ki Min; Dong-Gun Lee; Soo-Mi Choi; Ki-Seong Eom; Hee-Je Kim; Jong-Wook Lee; Woo-Sung Min; Chun-Choo Kim
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

8.  Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation.

Authors:  P J Shaughnessy; B J Bolwell; K van Besien; M Mistrik; A Grigg; A Dodds; H M Prince; S Durrant; O Ilhan; D Parenti; J Gallo; F Foss; J Apperley; M-J Zhang; M M Horowitz; S Abhyankar
Journal:  Bone Marrow Transplant       Date:  2009-11-16       Impact factor: 5.483

9.  Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation.

Authors:  K B Miller; D P Schenkein; R Comenzo; J K Erban; T Fogaren; C A Hirsch; E Berkman; A Rabson
Journal:  Ann Hematol       Date:  1994-01       Impact factor: 3.673

Review 10.  Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies.

Authors:  E H Warren; H J Deeg
Journal:  Tissue Antigens       Date:  2013-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.